Taiwan received its first batch of Pfizer-BioNTech vaccines Thursday after a prolonged purchasing process that gave rise to a political blame game with China.
Taiwan had been unable to buy the vaccine itself directly from BioNTech, the German company that had partnered with U.S.-based Pfizer to develop the mRNA vaccine.
Taiwanese President Tsai Ing-wen earlier accused China of blocking Taiwan from getting the Pfizer vaccine through BioNTech, saying that they had all but signed the contracts when the deal was delayed indefinitely. China has denied any interference.
Eventually, two private companies, Taiwan Semiconductor Manufacturing Corp. and Hon Hai Precision Electronics, as well as a Buddhist organization Tzu Chi, stepped in to buy the vaccines and donate them to Taiwan.
The three organizations bought a total of 15 million doses. The flight carrying the first 930,000 doses arrived at Taoyuan International Airport on Thursday morning.
Even their arrival has been dogged by politics. Local media at first reported Taiwan was getting doses ahead of schedule because they weren't needed in mainland China, where the Pfizer-BioNTech vaccine has not yet been cleared for use.
Health Minister Chen Shih-chung said last week that he had been told by TSMC that the vaccines would have simplified Chinese labels from China. Taiwan uses traditional, rather than simplified, Chinese characters. However, he emphasized that what mattered was the safety and the quality of the vaccine, not the labeling.
Chinese company Fosun Pharma has distribution rights for the vaccine in Greater China, a phrase Beijing says includes Taiwan. Fosun said on its social media Wednesday that it had supplied the batch of vaccines that was due to arrive.
The Pfizer-BioNTech vaccine will be given to 12-17-year-olds, Taiwan's Centers for Disease Control had said.
Taiwan has been using AstraZeneca, Moderna and the domestically made Medigen vaccine in its campaign so far and has vaccinated 43% of its population with at least one dose. The island's policy is to give out first doses widely.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)